Organigram Holdings Inc. (NASDAQ:OGI - Free Report) - Equities research analysts at Atb Cap Markets upped their FY2024 earnings per share estimates for Organigram in a report issued on Sunday, December 8th. Atb Cap Markets analyst F. Gomes now forecasts that the company will earn ($0.23) per share for the year, up from their prior estimate of ($0.25). The consensus estimate for Organigram's current full-year earnings is ($0.21) per share.
Organigram Stock Down 1.0 %
Shares of OGI traded down $0.02 during trading hours on Wednesday, reaching $1.53. The stock had a trading volume of 395,962 shares, compared to its average volume of 931,252. The company has a market cap of $166.10 million, a P/E ratio of -3.67 and a beta of 1.02. Organigram has a 52 week low of $1.20 and a 52 week high of $2.91. The firm has a 50-day moving average of $1.65 and a 200 day moving average of $1.68.
Institutional Investors Weigh In On Organigram
Several large investors have recently modified their holdings of the business. Clear Harbor Asset Management LLC acquired a new stake in shares of Organigram during the second quarter worth $51,000. Renaissance Technologies LLC raised its stake in shares of Organigram by 40.8% in the 2nd quarter. Renaissance Technologies LLC now owns 816,948 shares of the company's stock valued at $1,258,000 after purchasing an additional 236,700 shares during the period. AdvisorShares Investments LLC lifted its holdings in shares of Organigram by 11.8% in the second quarter. AdvisorShares Investments LLC now owns 1,000,126 shares of the company's stock valued at $1,540,000 after purchasing an additional 105,468 shares in the last quarter. Baader Bank Aktiengesellschaft lifted its holdings in shares of Organigram by 26.4% in the second quarter. Baader Bank Aktiengesellschaft now owns 252,852 shares of the company's stock valued at $388,000 after purchasing an additional 52,852 shares in the last quarter. Finally, Toronto Dominion Bank boosted its position in shares of Organigram by 803.7% during the third quarter. Toronto Dominion Bank now owns 16,727 shares of the company's stock worth $30,000 after buying an additional 14,876 shares during the period. 34.63% of the stock is currently owned by institutional investors.
About Organigram
(
Get Free Report)
Organigram Holdings Inc, through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co, Edison JOLTS, Tremblant, and Laurentian brands.
Further Reading
Before you consider Organigram, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Organigram wasn't on the list.
While Organigram currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
